Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Addition information on this. From Google AI:

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154592
(Total Views: 556)
Posted On: 02/19/2025 10:49:32 AM
Posted By: Buddyboy20
Re: sunray3 #150264
Addition information on this.

From Google AI:

"M2 macrophages, also known as tumor-associated macrophages (TAMs), are a type of macrophage that promote the growth and spread of cancer. They do this by suppressing the immune system, promoting angiogenesis, and supporting tumor cell proliferation.
How M2 macrophages promote cancer
Angiogenesis: M2 macrophages secrete VEGF, which promotes angiogenesis in tumors.
Immune suppression: M2 macrophages inhibit NK cell function by secreting inhibitory factors and through cell-cell contact.
Tumor cell proliferation: M2 macrophages promote cancer cell proliferation and invasion.
Metastasis: M2 macrophages facilitate metastasis.
Targeting M2 macrophages
Decoy oligodeoxynucleotides: Decoy ODNs can inhibit M2-like polarization and control tumor growth.
Blocking CSF-1/CSF-1 receptor and CCL2/CCR2 pathways: These pathways can be blocked to restrict the infiltration of TAMs.
Regulating TAM repolarization: Strategies can be developed to regulate TAM repolarization.
M2 macrophages and prognosis
A high proportion of M2-like macrophages in TAMs is associated with poor prognosis and shorter survival in many cancers.
Research on M2 macrophages
Research on M2 macrophages is ongoing to develop new therapeutic strategies to improve outcomes for cancer patients."



Leronlimab blocks CSF-1 receptor and CCL2/CCR2 pathways by blocking the CCR5 receptors. Additionally, blocking the CCR5 receptors reprograms the M2 macrophages (that the cancer had programmed) back to M1 macrophages, which will attack tumor cells and circulating tumor cells and help stop angiogenesis (redirected blood supply) to the cancer cells.

I'm sure Ohm20 can break it down even further.


(8)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us